MX2012001916A - Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos. - Google Patents

Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Info

Publication number
MX2012001916A
MX2012001916A MX2012001916A MX2012001916A MX2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A MX 2012001916 A MX2012001916 A MX 2012001916A
Authority
MX
Mexico
Prior art keywords
red blood
blood cell
cell levels
erythropoietin receptor
receptor activators
Prior art date
Application number
MX2012001916A
Other languages
English (en)
Inventor
Jasbir Seehra
Ravindra Kumar
Robert Scott Pearsall
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/583,177 external-priority patent/US8058229B2/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MX2012001916A publication Critical patent/MX2012001916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen composiciones para incrementar los niveles de glóbulos rojos o tratamiento de anemia que comprende activadores de receptor de eritropoyetina y un polipéptido de Activina RIIB (ActRIIB) variante teniendo un residuo de leucina reemplazado por un residuo de aminoácido ácido, en donde el polipéptido ActRIIB variante tiene una afinidad reducida para activina B y pueden ser denominados como una trampa GDF. También se describen métodos para el uso de estas composiciones.
MX2012001916A 2009-08-13 2010-08-13 Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos. MX2012001916A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US30590110P 2010-02-18 2010-02-18
PCT/US2010/045509 WO2011020045A1 (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Publications (1)

Publication Number Publication Date
MX2012001916A true MX2012001916A (es) 2012-05-22

Family

ID=43586530

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012001916A MX2012001916A (es) 2009-08-13 2010-08-13 Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.
MX2019010341A MX2019010341A (es) 2009-08-13 2012-02-13 Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010341A MX2019010341A (es) 2009-08-13 2012-02-13 Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.

Country Status (14)

Country Link
EP (3) EP2464369B1 (es)
JP (4) JP5909446B2 (es)
KR (5) KR20200124322A (es)
CN (7) CN113577291A (es)
AU (1) AU2010282361B2 (es)
BR (2) BR122020019169B1 (es)
CA (1) CA2770822C (es)
ES (2) ES2796121T3 (es)
HK (2) HK1223818A1 (es)
IL (6) IL287990B (es)
MX (2) MX2012001916A (es)
NZ (3) NZ598348A (es)
RU (2) RU2642302C1 (es)
WO (1) WO2011020045A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2484372A1 (en) 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) * 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
CA2852683A1 (en) * 2011-10-17 2013-04-25 Acceleron Pharma, Inc. Methods and compositions for treating ineffective erythropoiesis
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
ES2753811T3 (es) * 2012-10-24 2020-04-14 Celgene Corp Biomarcador para uso en el tratamiento de anemia
CN112957462A (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血的方法
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
CA2951926C (en) * 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3922259A1 (en) * 2014-10-30 2021-12-15 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
EP3256148A1 (en) * 2015-02-12 2017-12-20 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
SG11201708351XA (en) 2015-04-22 2017-11-29 Alivegen Usa Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
CA2986432A1 (en) * 2015-05-20 2016-11-24 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
AU2017222526A1 (en) * 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
RS62011B1 (sr) 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
KR20190040972A (ko) * 2016-07-27 2019-04-19 악셀레론 파마 인코포레이티드 골섬유증 치료 방법 및 조성물
JP7280182B2 (ja) * 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
AU2017340504A1 (en) 2016-10-05 2019-04-11 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
US11013785B2 (en) 2016-11-10 2021-05-25 Keros Therapeutics, Inc. Activin receptor type IIA variants and methods of use thereof
US20200101134A1 (en) 2017-06-14 2020-04-02 Celgene Corporation Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia
WO2019094751A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
JP2021518745A (ja) 2018-01-12 2021-08-05 ケロス セラピューティクス インコーポレイテッドＫｅｒｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． アクチビンｉｉｂ型受容体変異体およびそれらの使用方法
AU2019266314A1 (en) * 2018-05-09 2020-11-19 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP3873441A4 (en) * 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
CN115317589A (zh) * 2022-09-05 2022-11-11 中国海洋大学 脯氨酰羟化酶抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
NZ513642A (en) 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
WO2001087329A1 (en) * 2000-05-15 2001-11-22 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivate
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP2324834B1 (en) * 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
ZA200506246B (en) * 2003-02-07 2006-12-27 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
EP1819357A4 (en) * 2004-12-09 2009-02-25 Univ Pittsburgh VACCINES FOR FAST RESPONSE TO A BIRD GRIP PANDEMY
JPWO2006115274A1 (ja) * 2005-04-26 2008-12-18 味の素株式会社 骨髄赤血球前駆細胞分化促進剤
ES2370040T3 (es) * 2005-10-07 2011-12-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Vacuna de metaloproteinasa 11 de la matriz.
US8067562B2 (en) * 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
WO2008073292A2 (en) * 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
HRP20230761T1 (hr) * 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke

Also Published As

Publication number Publication date
CN105412908A (zh) 2016-03-23
IL252046A0 (en) 2017-06-29
EP3117829A1 (en) 2017-01-18
KR102170682B1 (ko) 2020-10-28
JP2020203953A (ja) 2020-12-24
IL252044B (en) 2019-11-28
HK1224199A1 (zh) 2017-08-18
JP2018177816A (ja) 2018-11-15
BR112012003232B1 (pt) 2022-02-22
CN105561295A (zh) 2016-05-11
KR20230003452A (ko) 2023-01-05
IL252045B (en) 2020-05-31
RU2017145301A3 (es) 2019-06-24
IL275851B (en) 2021-12-01
EP3117829B1 (en) 2020-10-07
RU2642302C1 (ru) 2018-01-24
EP2464369A4 (en) 2013-07-17
CN113577291A (zh) 2021-11-02
IL252044A0 (en) 2017-06-29
RU2592670C2 (ru) 2016-07-27
BR112012003232A2 (pt) 2016-11-22
IL218052A0 (en) 2012-04-30
RU2017145301A (ru) 2019-06-24
NZ712943A (en) 2017-08-25
CN113082194A (zh) 2021-07-09
ES2796121T3 (es) 2020-11-25
RU2732229C2 (ru) 2020-09-14
CA2770822C (en) 2020-03-24
JP5909446B2 (ja) 2016-04-26
CN113171442A (zh) 2021-07-27
KR20200124322A (ko) 2020-11-02
WO2011020045A9 (en) 2011-06-03
EP3838919A1 (en) 2021-06-23
RU2012109393A (ru) 2013-09-20
JP2016034981A (ja) 2016-03-17
KR20190111158A (ko) 2019-10-01
RU2020127574A (ru) 2022-02-21
EP2464369B1 (en) 2020-03-11
JP6860533B2 (ja) 2021-04-14
CN105535938B (zh) 2022-04-26
KR20120054024A (ko) 2012-05-29
IL218052A (en) 2017-05-29
AU2010282361B2 (en) 2015-03-19
JP2013501816A (ja) 2013-01-17
AU2010282361A1 (en) 2012-03-15
ES2844123T3 (es) 2021-07-21
KR20180085825A (ko) 2018-07-27
IL252046B (en) 2020-07-30
IL287990A (en) 2022-01-01
IL252045A0 (en) 2017-06-29
HK1223818A1 (zh) 2017-08-11
CN102655872A (zh) 2012-09-05
CN102655872B (zh) 2016-01-20
BR122020019169B1 (pt) 2022-09-27
IL275851A (en) 2020-08-31
EP2464369A1 (en) 2012-06-20
NZ598348A (en) 2014-05-30
CN105561295B (zh) 2020-03-20
CN105412908B (zh) 2021-08-24
KR101882521B1 (ko) 2018-07-27
CA2770822A1 (en) 2011-02-17
MX2019010341A (es) 2019-10-21
NZ623113A (en) 2015-10-30
KR102606494B1 (ko) 2023-11-24
CN105535938A (zh) 2016-05-04
WO2011020045A1 (en) 2011-02-17
IL287990B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
MX2019010341A (es) Uso combinado de trampas gdf y activadores del receptor de eritropoyetina para incrementar los niveles de globulos rojos.
JOP20180102B1 (ar) مركب صيدلاني
EA201590887A1 (ru) Композиция
EA201201036A1 (ru) Целевые геномные изменения
WO2011139702A3 (en) Modified nucleosides and oligomeric compounds prepared therefrom
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
IN2014DN09346A (es)
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MX2013001580A (es) Composiciones que comprenden un polipeptido que tiene actividad de incremento celulolitico y un licor, y usos de las mismas.
MY161534A (en) Methods of purifying polypeptides
BR112014015905A8 (pt) composição
BR112014015908A2 (pt) composição
TR201905272T4 (tr) İmmünojenik bileşim.
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
EA201201623A1 (ru) Лечение диабета 2 типа
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2010120541A3 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
PH12014501781A1 (en) Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
UA113540C2 (xx) Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду
MX339361B (es) Derivados de alternano.
EA201370247A1 (ru) Гипертония и гиперурикемия
WO2013192238A3 (en) Compositions and methods for treatment of diabetes

Legal Events

Date Code Title Description
FG Grant or registration